First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose
These results demonstrate the potential benefits of heterologous boosting (mix-and-match). The article describing these results have been posted on medRxiv
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
Subscribe To Our Newsletter & Stay Updated
